Integer Holdings Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Integer Holdings, alleging violations of federal securities laws from July 25, 2024, to October 22, 2025, seeking to recover losses for investors.
- False Statements Allegation: The complaint alleges that Integer made materially false and misleading statements during this period, failing to disclose that its competitive position in the EP manufacturing market was significantly overstated, misleading investors about the company's prospects.
- Sales Decline Concealment: Despite Integer's claims of strong visibility into customer demand, the company was experiencing a sustained decline in sales of two EP devices, which misrepresented its operational status and undermined investor confidence.
- Investor Rights Protection: Affected investors have until February 9, 2026, to apply as lead plaintiffs, with Bronstein, Gewirtz & Grossman LLC offering legal support on a contingency fee basis, ensuring investor rights are upheld.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 86.230
Low
75.00
Averages
93.38
High
140.00
Current: 86.230
Low
75.00
Averages
93.38
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
